Latest revenue
$328.5M
as of 2026-03-31
Latest net income
$24.2M
as of 2026-03-31
Net margin
7.4%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.95B
- Enterprise value
- $1.95B
- P/E (trailing)
- 33.3×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $28.75
- 52-wk low
- $16.10
- Beta
- —
- Shares out
- 78.3M
5-year trend
What this company does
ITEM 1. BUSINESS Overview Progyny is a global leader in women’s health and family building solutions. We envision a world where everyone can realize their dreams of family and ideal health. Our mission is to empower healthier, supported journeys through transformative fertility, family building and women’s health benefits. Through our differentiated approach to benefits plan design, member education and support and active network management, our clients’ employees are able to pursue the most effective treatment across life’s milestones from the best providers and specialists and achieve optimal outcomes. We launched our fertility benefits solution in 2016 with five employer clients and have…
AI summary unavailable — showing raw filing excerpt
Generated from PGNY's filing dated 2026-02-27
Key risks
Table of Contents ITEM 1A. RISK FACTORS Investing in our common stock involves a high degree of risk. You should carefully consider all of the information contained in this Annual Report on Form 10-K, including the sections titled “Cautionary Note Regarding Forward-Looking Statements,” Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and the accompanying notes included elsewhere in this Annual Report on Form 10-K. The risks and uncertainties described below are not the only ones we face. Any of the following risks could materially and adversely affect our business, financial condition and…
AI summary unavailable — showing raw filing excerpt
Generated from PGNY's filing dated 2026-02-27
Profitability
Gross margin
23.6%
8.9%Operating margin
6.6%
14.5%Net margin
4.5%
2.4%Return on equity
11.3%
11.9%Return on assets
7.9%
11.9%Leverage
Debt / equity
0.44×
0.1%Debt / assets
30.5%
0.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $328.5M | +1.4% | $24.2M | +60.9% | 7.4% |
Q4 2025 2025-12-31 | $318.4M | +6.7% | $12.5M | +18.5% | 3.9% |
Q3 2025 2025-09-30 | $313.3M | +9.3% | $13.9M | +33.0% | 4.4% |
Q2 2025 2025-06-30 | $332.9M | +9.5% | $17.1M | +3.8% | 5.1% |
Q1 2025 2025-03-31 | $324.0M | +16.5% | $15.1M | -10.9% | 4.6% |
Q4 2024 2024-12-31 | $298.4M | — | $10.5M | — | 3.5% |
Q3 2024 2024-09-30 | $286.6M | +2.0% | $10.4M | -34.5% | 3.6% |
Q2 2024 2024-06-30 | $304.1M | +8.8% | $16.5M | +10.0% | 5.4% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Misc Health & Allied Services, NEC · SIC 8090
Your notes
Keep private notes on PGNY — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$1.9M
Insider selling
$1.4M
Net activity
+$529.8K
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns PGNY
No institutional holdings on file for PGNY yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once PGNY's latest filing finishes processing.